These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

977 related articles for article (PubMed ID: 22079980)

  • 1. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
    Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
    J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
    J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
    Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
    Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters.
    Baharia RK; Tandon R; Sahasrabuddhe AA; Sundar S; Dube A
    PLoS One; 2014; 9(6):e97911. PubMed ID: 24926878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.
    Khare P; Jaiswal AK; Tripathi CD; Joshi S; Sundar S; Dube A
    Parasitol Res; 2014 Mar; 113(3):851-62. PubMed ID: 24370734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis.
    Gupta R; Kushawaha PK; Tripathi CD; Sundar S; Dube A
    Int J Parasitol; 2012 May; 42(5):429-35. PubMed ID: 22502587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
    J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.
    Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A
    PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.
    Kumari S; Samant M; Khare P; Sundar S; Sinha S; Dube A
    Vaccine; 2008 Sep; 26(37):4813-8. PubMed ID: 18656517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
    Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.
    Khare P; Jaiswal AK; Tripathi CD; Sundar S; Dube A
    Clin Exp Immunol; 2016 Aug; 185(2):165-79. PubMed ID: 26898994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
    Garg R; Gupta SK; Tripathi P; Hajela K; Sundar S; Naik S; Dube A
    Vaccine; 2006 Apr; 24(15):2900-9. PubMed ID: 16448729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.
    Garg R; Gupta SK; Tripathi P; Naik S; Sundar S; Dube A
    Clin Exp Immunol; 2005 Apr; 140(1):149-56. PubMed ID: 15762886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
    Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
    Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.
    Gupta R; Kumar V; Kushawaha PK; Tripathi CP; Joshi S; Sahasrabuddhe AA; Mitra K; Sundar S; Siddiqi MI; Dube A
    PLoS One; 2014; 9(1):e86073. PubMed ID: 24475071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.